Wu et al. [37] first confirmed the specific therapeutic effect of HDW on liver cancer angiogenesis, then screened out 7 active compounds according to the pharmacokinetic characteristics of HDW, and further found through enrichment analysis and network analysis that these active compounds play an anti-angiogenesis role in liver cancer by acting on multiple targets, mainly involving IL-17 and IL-6. The gene discussed is IL17A; the disease is liver cancer.